Moe Alsumidaie's profile photo

Moe Alsumidaie

San Diego

Editor-in-Chief at Clinical Trial Vanguard

#Clinicaltrial strategist and #datascience expert pushing innovation in the biopharmaceutical industry.

Featured in: Favicon ajmc.com Favicon pharmexec.com Favicon appliedclinicaltrialsonline.com Favicon clinicaltrialvanguard.com Favicon clinicalleader.com

Articles

  • Revolutionizing Oncology Trials in India Through Digital Innovation

    3 days ago | clinicaltrialvanguard.com | Moe Alsumidaie

    In this interview with Dr. Seema Rajsingh, Executive Medical Director and Jarem Edwards, Clinical Scientist – Early Drug Development of Pi Health, a health technology and clinical research company transforming global access to innovative medicines and clinical trials through its proprietary AI-powered technology platform, we explore the challenges and opportunities in India’s oncology trial landscape. Despite housing 20% of the global population, India conducts only 2% of global oncology trials.

  • Behavioral Science: The Untapped Asset in Obesity Trial Strategy

    4 days ago | clinicaltrialvanguard.com | Moe Alsumidaie

    The global obesity epidemic has shifted from a public health issue to a fiercely competitive pharmaceutical frontier. With GLP-1 drugs like semaglutide and tirzepatide revolutionizing treatment and generating unprecedented commercial interest, analysts project the obesity drug market will surpass $200 billion in annual value by 2031.

  • Elevating Clinical Trial Imaging to a First-Class Data Role

    1 week ago | clinicaltrialvanguard.com | Moe Alsumidaie

    In this conversation with Jeffrey Sorenson, CEO at Yunu, we explore the transformative potential of treating imaging data as a first-class citizen in clinical trials. Sorenson, who spearheads innovative imaging solutions, discusses the necessary structural shifts in clinical trial protocols, the integration of advanced data systems, and the future of imaging in oncology studies.

  • How FDA's Guidance On Decentralized Trials Applies To Community-Cased Research Execution And Compliance

    1 week ago | clinicalleader.com | Moe Alsumidaie

    By Clinical Trial Vanguard and Moe AlsumidaieThe FDA's September 2024 guidance on decentralized clinical trials (DCTs) marks a pivotal shift in clinical research, recognizing the growing integration of decentralized elements like in-home visits, mobile research sites, and telehealth within a regulated framework. This approach is designed to expand accessibility, improve diversity, and enhance participant retention without sacrificing data integrity or safety.

  • FDA Dropped Diversity But Good Science Depends On It

    2 weeks ago | clinicaltrialvanguard.com | Moe Alsumidaie

    In this conversation, Thad Wolfram, Chief Strategy Officer of EmVenio Research and PCM Trials, shares his insights on the critical importance of inclusivity in clinical research, the impact of regulatory changes, and the role of community-based research in advancing medical science. Research should factor race, age, sex at birth, socioeconomic and demographic diversity.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers
930
Tweets
3K
DMs Open
Yes
No Tweets found.